Activation of protein-tyrosine kinase pathways in human platelets stimulated with the A1 domain of von Willebrand factor

Platelets

Volumn 11, Issue 3, 2000, Pages 171-176

  Satoh, Kaneo ^a   Asazuma, Naoki ^a   Yatomi, Yutaka ^a   Fujimura, Yoshihiro ^b   Miura, Shuji ^b   Titani, Koiti ^c   Ozaki, Yukio ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

GP, glycoprotein; MoAb, monoclonal antibody; VWF, Von Willebrand Factor; Ca2+ (i), intracellular Ca2+ concentration

Indexed keywords

CALCIUM ION; GLYCOPROTEIN IB; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; THROMBOCYTE RECEPTOR; VON WILLEBRAND FACTOR;

AGONIST; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

THROMBUS;

EID: 0034129283     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/095371000403116     Document Type: Article

References (32)

1. 1. Ruggeri Z M. von Willebrand factor. J Clin Invest 1997; 99: 559-64.
2. 2. Ruggeri Z M. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994; 31: 229-39.
3. 3. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri Z M. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
4. 4. Fujimura Y, Titani K, Holland L Z, Russell S R, Roberts J R, Elder J H, Ruggeri Z M, Zimmerman T S. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-5.
5. 5. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-401.
6. 6. Bertolino G, Noris P, Spedini P, Balduini C L. Ristocetin-induced platelet agglutination stimulates GPIIb/IIIa-dependent calcium influx. Thromb Haemostas 1995; 73: 689-92.
7. 7. Chow T W, Hellums J D, Moake J L, Kroll M H. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-20.
8. 8. Kroll M H, Hellums J D, Guo Z, Durante W, Razdan K, Hrbolich J K, Schafer AI. Protein kinase C is activated in platelets subjected to pathological shear stress. J Biol Chem 1993; 268: 3520-4.
9. 9. Asazuma N, Ozaki Y, Satoh K, Yatomi Y, Handa M, Fujimura Y, Miura S, Kume S. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. Blood 1997; 90: 4789-98.
10. 10. Cruz M A, Yuan H, Lee J R, Wise R J, Handin R I. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF A domain polypeptides. J Biol Chem 1995; 270: 10822-7.
11. 11. Cruz M A, Handin R I, and Wise R J. The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol Chem 1993; 268: 21238-45.
12. 12. Miyata S, Goto S, Federici A B, Ware J, Ruggeri Z M. Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha. J Biol Chem 1996; 271: 9046-53.
13. 13. Du X P, Plow E F, Frelinger AL I I I, O'Toole T E, Loftus J C, Ginsberg M H. Ligands 'activate' integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-16.
14. 14. Lefkovits J, Plow E F, Topol E J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New Engl J Med 1995; 332: 1553-9.
15. 15. Miura S, Fujimura Y, Sugimoto M, Kawasaki T, Ikeda Y, Titani K, Yoshioka A. Structural elements influencing von Willebrand factor (vWF) binding affinity for platelet glycoprotein Ib within a dispase-digested vWF fragment. Blood 1994; 84: 1553-8.
16. 16. Fujimura Y, Titani K, Usami Y, Suzuki M, Oyama R, Matsui T, Fukui H, Sugimoto M, Ruggeri Z M. Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca. Biochemistry 1991; 30: 1957-64.
17. 17. Fujimura Y, Ikeda Y, Miura S, Yoshida E, Shima H, Nishida S, Suzuki M, Titani K, Taniuchi Y, Kawasaki T. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. Thromb Haemostas 1995; 74: 743-50.
18. syk in human platelets. J Biol Chem 1995; 270: 15119-24.
19. 2+ store depletion. J Immunol 1995; 155: 4427-36.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
21. 21. Miura S, Nishida S, Makita K, Sakurai Y, Shimoyama T, Sugimoto M, Yoshida A, Ishii K, Kito M, Kobayashi T, Fujimura Y. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. Anal Biochem 1996; 236: 215-20.
22. syk expressed in hematopoietic cells. Cell Signalling 1995; 7: 185-93.
23. 23. Jackson S P, Schoenwaelder S M, Yuan Y, Salem H H, Cooray P. Non-receptor protein tyrosine kinases and phosphatases in human platelets. Thromb Haemostas 1996; 76: 640-50.
24. 24. Ozaki Y, Satoh K, Yatomi Y, Miura S, Fujimura Y, Kume S. Protein tyrosine phosphorylation in human platelets induced by interaction between glycoprotein Ib and von Willebrand factor. Biochim Biophys Acta 1995; 1243: 482-8.
25. 25. Ruggeri Z M, Mannucci P M, Lombardi R, Federici A B, Zimmerman T S. Ultimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982; 59: 1272-8.
26. 26. Weiss H J, Pietu G, Rabinowitz R, Girma J P, Rogers J, Meyer D. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med 1983; 101: 411-25.
27. syk activation by an anti-glycoprotein Ib monoclonal antibody. Blood 1997; 89: 1590-8.
28. 28. Schulte am Esch J ii, Cruz M A, Siegel J B, Anrather J, Robson S C. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood 1997; 90: 4425-37.
29. 29. Joseph J E, Machin S J. New antiplatelet drugs. Blood Rev 1997; 11: 178-90.
30. 30. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. New Engl J Med 1994; 330: 956-61.
31. 31. Yamamoto H, Vreys I, Stassen J M, Yoshimoto R, Vermylen J, Hoylaerts M F. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemostas 1998; 79: 202-10.
32. 32. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol 1997; 122: 165-71.